SMARCA4-deficient sarcoma of thorax
MONDO:0018761Also known as: SMARCA4-deficient thoracic sarcoma
2824 clinical trials for this condition and its sub-types, 8 tagged with SMARCA4-deficient sarcoma of thorax itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…
Phase 1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for sarcoma patients: immunotherapy plus chemo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC